NO20043971L - Anti-CCR5 antistoff - Google Patents

Anti-CCR5 antistoff

Info

Publication number
NO20043971L
NO20043971L NO20043971A NO20043971A NO20043971L NO 20043971 L NO20043971 L NO 20043971L NO 20043971 A NO20043971 A NO 20043971A NO 20043971 A NO20043971 A NO 20043971A NO 20043971 L NO20043971 L NO 20043971L
Authority
NO
Norway
Prior art keywords
atcc deposit
deposit designation
plasmid designated
designation pta
ccr5
Prior art date
Application number
NO20043971A
Other languages
English (en)
Inventor
Naoya Tsurushita
William C Olson
Paul J Maddon
Paul R Hinton
Maximillano Vasquez
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of NO20043971L publication Critical patent/NO20043971L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen er rettet på et anti-CCR5-antistoff som omfatter (i) to lette kjeder, hvor hver lette kjede omfatter ekspresjonsproduktet av et plasmid betegnet pVK:HuPRO140-VK (ATCC-deponeringsbetegnelse PTA-4097), og (ii) to tunge kjeder, hvor hver tunge kjede omfatter ekspresjonsproduktet av enten et plasmid betegnet pVgl:HuPRO140 HG2-VH (ATCC-deponeringsbetegnelse PTA-4098) eller et plasmid betegnet pVgl:HuPRO140 (mut B+D+I)-VH (ATCC-deponeirngsbetegnelse PTA-4099) eller et fragment av et slikt antistoff som bindes til CCR5 på overflaten av en menneskecelle.
NO20043971A 2002-02-22 2004-09-22 Anti-CCR5 antistoff NO20043971L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8112802A 2002-02-22 2002-02-22
PCT/US2003/005500 WO2003072766A1 (en) 2002-02-22 2003-02-21 Anti-ccr5 antibody

Publications (1)

Publication Number Publication Date
NO20043971L true NO20043971L (no) 2004-11-16

Family

ID=27765254

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043971A NO20043971L (no) 2002-02-22 2004-09-22 Anti-CCR5 antistoff

Country Status (19)

Country Link
EP (2) EP2058006A1 (no)
JP (1) JP2006508631A (no)
KR (1) KR20050004784A (no)
CN (1) CN1780907B (no)
AT (1) ATE414142T1 (no)
AU (1) AU2003217674C1 (no)
CA (1) CA2476901C (no)
CY (1) CY1108799T1 (no)
DE (1) DE60324664D1 (no)
DK (1) DK1478738T3 (no)
ES (1) ES2316740T3 (no)
IL (1) IL163655A0 (no)
MX (1) MXPA04008153A (no)
NO (1) NO20043971L (no)
NZ (2) NZ561465A (no)
PT (1) PT1478738E (no)
RU (1) RU2322454C2 (no)
WO (1) WO2003072766A1 (no)
ZA (1) ZA200406765B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
KR20080035653A (ko) * 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
KR101105610B1 (ko) 2006-08-17 2012-01-18 에프. 호프만-라 로슈 아게 Ｃｃｒ５ 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
CA2664752A1 (en) 2006-09-29 2008-04-03 F. Hoffmann-La Roche Ag Antibodies against ccr5 and uses thereof
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
CA2736029A1 (en) * 2008-09-05 2010-03-11 Duke University Anti-lipid antibodies
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US11584797B2 (en) 2015-06-23 2023-02-21 Cytodyn Inc. Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions
WO2017087547A1 (en) * 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
EP4090675A4 (en) * 2020-01-13 2024-02-21 CytoDyn Inc. CCR5 BINDING AGENT FOR THE TREATMENT OF CCR5-POSITIVE METASTATIC BREAST CANCER
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH03505579A (ja) * 1988-06-30 1991-12-05 デービス，マイクル，エイチ ヒト免疫不全ウイルス（ｈｉｖ）のインビボにおける活性の阻害方法
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
DK1144006T3 (da) * 1998-12-16 2007-11-26 Progenics Pharm Inc Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil
JP3459386B2 (ja) 1999-10-15 2003-10-20 Ｓｍｃ株式会社 可逆式取付機構を有する流体圧機器
US20030049251A1 (en) * 1999-12-08 2003-03-13 Barbas Carlos F. Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease

Also Published As

Publication number Publication date
PT1478738E (pt) 2009-02-16
MXPA04008153A (es) 2005-07-05
DK1478738T3 (da) 2009-03-09
EP2058006A1 (en) 2009-05-13
EP1478738A4 (en) 2006-05-31
NZ534947A (en) 2008-03-28
EP1478738B1 (en) 2008-11-12
RU2322454C2 (ru) 2008-04-20
EP1478738A1 (en) 2004-11-24
AU2003217674A1 (en) 2003-09-09
IL163655A0 (en) 2005-12-18
AU2003217674C1 (en) 2009-03-26
DE60324664D1 (de) 2008-12-24
WO2003072766A1 (en) 2003-09-04
CN1780907B (zh) 2011-06-15
CA2476901C (en) 2012-10-09
ATE414142T1 (de) 2008-11-15
CY1108799T1 (el) 2014-04-09
RU2004128252A (ru) 2005-04-10
NZ561465A (en) 2009-04-30
CN1780907A (zh) 2006-05-31
JP2006508631A (ja) 2006-03-16
KR20050004784A (ko) 2005-01-12
ES2316740T3 (es) 2009-04-16
HK1072272A1 (en) 2005-08-19
ZA200406765B (en) 2006-06-28
AU2003217674B2 (en) 2008-10-30
CA2476901A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
CY1108799T1 (el) Αντισωμα αντι- ccr5
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
CY1115730T1 (el) Θεραπευτικοι επιτοποι και χρησεις αυτων
PT778891E (pt) Anticorpo monoclonal recombinante anti-rhesus d (d7c2)
CO4480111A1 (es) Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
DE69327229D1 (de) Multivalente einkettige Antikörper
FI4209510T3 (fi) Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
ATE479710T1 (de) Bispezifische antikörper
IN2009KN02655A (no)
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
NZ590690A (en) Antibodies that bind to p-selectin glycoprotein ligand 1
DK0679094T3 (da) Forbindelser til målretning
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
IN2014DN05011A (no)
EP1712565A4 (en) CELL-DOD INDUCING MEANS
FR2841905B1 (fr) Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
EP2267034A3 (en) Gold-binding protein and use thereof
PE20090906A1 (es) Anticuerpos y fragmentos de anticuerpos anti ephb4
WO2004050849A8 (en) Recombinant immunotoxin and use in treating tumors
WO2004029214A3 (en) Lfa-1 alpha subunit antibodies and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application